1621375-32-3
1621375-32-3
Chemical Structure
VPC-14449
- CAS No.: 1621375-32-3
- Formula:C10H10Br2N4OS
- Molecular Weight:394.09
IUPAC Name: 4-(4-(2,4-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine
InChIKey: AZLNRGRZOLVWRX-UHFFFAOYSA-N
SMILES: BrC1=CN(C2=CSC(N3CCOCC3)=N2)C(Br)=N1
Biological Activity: VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
VPC-14449 | 99.51% | VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dalal K, et, al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289(38):26417-26429. [Content Brief]
- [2]. Dalal K, et, al. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. Mol Cancer Ther. 2017 Oct;16(10):2281-2291. [Content Brief]
Keywords
